Hintermann Series H3 Total Ankle Replacement System
Dt Medtech, LLC · Decision date Jul 31, 2026
What did the FDA approve?
FDA records P160036/S008 as a supplement to PMA P160036, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 31, 2026.
FDA approval order statement
The second post-approval study (PAS002, Hintermann Series H3 TAR Performance Study) is designed to evaluate the trend in performance between each implant size and assess the outcomes of the primary surgeon of the study (accounting for approximately 80% of the registry) compared to other surgeons that are less familiar with the device. You agree to use a prospective, multicenter, single arm study design, and hypothesis testing to evaluate the performance of the different implant sizes of the Hintermann Series H3 TAR System compared to the Hintermann Series H3 TAR System performance in the PSE cohort. Multiple investigators unfamiliar with the device will be recruited so that one surgeon does not conduct the majority of the cases and to evaluate the impact of experience on overall outcomes. You have agreed to enroll 232 new study subjects at up to 10 US sites and to follow these subjects for 5 years. Study subjects will undergo clinical and radiographic evaluation postoperatively at 6 weeks, 6 months, and yearly afterwards. You have agreed to take reasonable measures to avoid loss to follow-up. A follow-up rate of 85% is expected at each timepoint. You have agreed to collect and analyze information about safety, including any reoperation, revisions or removals of the Hintermann Ankle device, and effectiveness endpoints, including the American Orthopaedic Foot and Ankle Society at 2 years or more, the survivorship (absence of removal/revisions to include polyethylene revision) within 5 years, the percentage of subjects with a serious device-related adverse event other than a revision or removal within 2 years, as well as VAS score, patient satisfaction, and SF-36 for general well-being. You will also collect information about all adverse events reported for these patients, including details of the nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome. Additionally, you have agreed to provide radiographic assessments of all enrolled subjects as well as a detailed explant analysis of any explanted devices during the PAS.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Orthopedic
- Decision date
- Jul 31, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P160036/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Dt Medtech, LLC
- Product code
- NTG
- Decision code
- APPR
- Decision date
- Jul 31, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, ankle, uncemented, non-constrained.
- Applicant
- Dt Medtech, LLC
- Product code
- NTG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160036/S008 received
Application receipt date recorded by FDA.
P160036/S008 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P160036. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Dt Medtech, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 110 W. Rd., Suite 227, Towson, MD, 21204
Sources and methodology
- Original FDA record: P160036/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records